Can Dietary Methionine Restriction Increase the Effectiveness of Chemotherapy in Treatment of Advanced Cancer?

Journal of the American College of Nutrition

Volumn 20, Issue , 2001, Pages 443S-449S

  Epner, Daniel E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer treatment; Chemotherapy; Methionine restriction; Synergism

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; METHIONINE; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL GROWTH; CONFERENCE PAPER; DIET RESTRICTION; DIETARY INTAKE; GASTROINTESTINAL CARCINOMA; HUMAN; LUNG CARCINOMA; METASTASIS; PROSTATE CARCINOMA; TREATMENT PLANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; HUMANS; METHIONINE; NEOPLASM METASTASIS; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; SAFETY; TREATMENT OUTCOME;

EID: 0034790974     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2001.10719183     Document Type: Article

References (88)

1. American Institute for Cancer Research. “Food, Nutrition and the Prevention of Cancer: A Global Perspective.” World Cancer Research Fund, American Institute for Cancer Research, 1997.
2. Drummond JC: A comparative study of tumor and normal tissue growth. Biochem J 11: 825, 1917.
3. Sugimura T, Birnbaum SM, Winitz M, Greenstein JP: Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys 81: 448-455, 1959.
4. Lorincz AB, Kuttner RE, Brandt MB: Tumor response to phenylalanine-tyrosine-limited diets. J Am Diet Assoc 54: 198-205, 1969.
5. Lawson DH, Stockton LH, Bleier JC, Acosta PB, Heymsfield SB, Nixon, DW: The effect of a phenylalanine and tyrosine restricted diet on elemental balance studies and plasma aminograms of patients with disseminated malignant melanoma. Am J Clin Nutr 41: 73-84, 1985.
6. Demopoulos HB: Effects of reducing the phenylalanine-tyrosine intake of patients with advanced malignant melanoma. Cancer 19: 657-664, 1966.
7. Pelayo BA, Fu YM, Meadows GG: Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors. Clin Exp Metastasis 17: 841-848, 1999.
8. Fu YM, Yu ZX, Pelayo BA, Ferrans VJ, Meadows GG: Focal adhesion kinase-dependent apoptosis of melanoma induced by tyrosine and phenylalanine deficiency. Cancer Res 59: 758-765, 1999.
9. Hoffman RM, Erbe RW: High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA 73: 1523-1527, 1976.
10. Stern PH, Hoffman RM: Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76: 629-639, 1986.
11. Du Vigneaud V, Chandler JP, Moyer AW, Keppel DM: The effect of choline on the ability of homocysteine to replace methionine in the diet. J Biol Chem 131: 57-76, 1939.
12. Breillout F, Hadida F, Echinard-Garin P, Lascaux V, Poupon MF: Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet. Anticancer Res 7: 861-867, 1987.
13. Kreis W: Tumor therapy by deprivation of L-methionine: rationale and results. Cancer Treat Rep 63: 1069-1072, 1979.
14. Tisdale M, Eridani S: Methionine requirement of normal and leukaemic haemopoietic cells in short term cultures. Leuk Res 5: 385-394, 1981.
15. Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM: The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 117: 429-434, 1983.
16. Stern PH, Wallace CD, Hoffman RM: Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119: 29-34, 1984.
17. Breillout F, Antoine E, Poupon MF: Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 82: 1628-1632, 1990.
18. Poirson-Bichat F, Gonfalone G, Bras-Goncalves RA, Dutrillaux B, Poupon, MF: Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by methionine combined with methionine starvation. Br J Cancer 75: 1605-1612, 1997.
19. Guo H, Lishko VK, Herrera H, Groce A, Kubota T, Hoffman RM: Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Research 53: 5676-5679, 1993.
20. Goseki N, Onodera T, Koike M, Kosaki G: Inhibitory effect of L-methionine-deprived amino acid imbalance using total parenteral nutrition on growth of ascites hepatoma in rats. Tohoku J Exp Med 151: 191-200, 1987.
21. Millis RM, Diya CA, Reynolds ME: Growth inhibition of subcutaneously transplanted hepatomas by alterations of the dietary arginine-methionine balance. Nutr Cancer 25: 317-327, 1996.
22. Millis RM, Diya CA, Reynolds ME, Dehkordi O, Bond VJ: Growth inhibition of subcutaneously transplanted hepatomas without cachexia by alteration of the dietary arginine-methionine balance. Nutr Cancer 31: 49-55, 1998.
23. Guo HY, Herrera H, Groce A, Hoffman RM: Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 53: 2479-2483, 1993.
24. Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, Koh J, Kitajima M, Hoffman RM: Human tumors are methionine dependent in vivo. Anticancer Res 15: 717-718, 1995.
25. Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Wang X, An Z, Sun FX, Hoffman RM: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5: 2157-2163, 1999.
26. Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM, Sugita K: Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 58: 2583-2587, 1998.
27. Tan Y, Xu M, Guo H, Sun X, Kubota T, Hoffman RM: Anticancer efficacy of methioninase in vivo. Anticancer Res 16: 3931-3936, 1996.
28. Kreis W, Hession C: Biological effects of enzymatic deprivation of L-methionine in cell culture and an experimental tumor. Cancer Res 33: 1866-1869, 1973.
29. Tisdale MJ, Jack GW, Eridani S: Differential sensitivity of normal and leukaemic haemopoietic cells to methionine deprivation by L-methioninase. Leuk Res 7: 269-277, 1983.
30. Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM, Sugita K: Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 58: 2583-2587, 1998.
31. Kokkinakis DM, Schold SCJ, Hori H, Nobori T: Effect of longterm depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice. Nutr Cancer 29: 195-204, 1997.
32. Kreis W, Baker A, Ryan V, Bertasso A: Effect of nutritional and enzymatic methionine deprivation upon human normal and malignant cells in tissue culture. Cancer Res 40: 634-641, 1980.
33. Miki K, Al-Refaie W, Xu M, Jiang P, Tan Y, Bouvet M, Zhao M, Gupta A, Chishima T, Shimada H, Makuuchi M, Moossa AR, Hoffman RM: Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Cancer Res 60: 2696-2702, 2000.
34. Miki K, Xu M, An Z, Wang X, Yang M, Al-Refaie W, Sun X, Baranov E, Tan Y, Chishima T, Shimada H, Moossa AR, Hoffman RM: Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model. Cancer Gene Ther 7: 332-338, 2000.
35. Tan Y, Zavala JS, Xu M, Zavala JJ, Hoffman RM: Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients. Anticancer Res 16: 3937-3942, 1996.
36. Tan Y, Zavala JS, Han Q, Xu M, Sun X, Tan X, Magana R, Geller J, Hoffman RM: Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res 17: 3857-3860, 1997.
37. Tan Y, Sun X, Xu M, An Z, Tan X, Tan X, Han Q, Miljkovic DA, Yang M, Hoffman RM: Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expr Purif 12: 45-52, 1998.
38. Tan Y, Sun X, Xu M, An Z, Tan X, Han Q, Miljkovic DA, Yang M, Hoffman RM: Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expr Purif 12: 45-52, 1998.
39. Stern PH, Hoffman RM: Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 20: 663-670, 1984.
40. Tisdale MJ: Effect of methionine deprivation on methylation and synthesis of macromolecules. Br J Cancer 42: 121-128, 1980.
41. Judde JG, Ellis M, Frost P: Biochemical analysis of the role of transmethylation in the methionine dependence of tumor cells. Cancer Res 49: 4859-4865, 1989.
42. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-96, 1998.
43. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481, 1997.
44. Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA, James SJ: Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyldeficient rats. Cancer Res 55: 1894-1901, 1995.
45. Davey C, Pennings S, Allan J: CpG methylation remodels chromatin structure in vitro. J Mol Biol 267: 276-288, 1997.
46. Razin A: CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 17: 4905-4908, 1998.
47. Wolffe A: Chromatin Structure. In: “Chromatin: Structure and Function.” San Diego: Academic Press, pp 7-172, 1998.
48. “Polyamines in Cancer: Basic Mechanisms and Clinical Approaches.” Austin, Texas: R.G. Landes Company, 1996.
49. Beckman KB, Ames BN: Oxidative decay of DNA. J Biol Chem 272: 19633-19636, 1997.
50. Davies KJ: Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 61: 1-31, 1995.
51. Chen X, Carystinos GD, Batist G: Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 111-112: 263-275, 1998.
52. Calvert P, Yao KS, Hamilton TC, O’Dwyer PJ: Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 111-112: 213-224, 1998.
53. Fernandez-Checa JC, Maddatu T, Ookhtens M, Kaplowitz N: Inhibition of GSH efflux from rat liver by methionine: effects of GSH synthesis in cells and perfused organ. Am J Physiol 258: G967-G973, 1990.
54. Aw TY, Ookhtens M, Kaplowitz N: Inhibition of glutathione efflux from isolated rat hepatocytes by methionine. J Biol Chem 259: 9355-9358, 1984.
55. Guo H, Tan Y, Kubota T, Moossa AR, Hoffman RM: Methionine depletion modulates the antitumor and antimetastatic efficacy of methionine. Anticancer Res 16: 2719-2723, 1996.
56. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B, Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 6: 643-653, 2000.
57. Sasamura T, Matsuda A, Kokuba Y: Effects of D-methioninecontaining solution on tumor cell growth in vitro. Arzneimittelforschung 49: 541-543, 1999.
58. Sasamura T, Matsuda A, Kokuba Y: Nutritional effects of a Dmethionine-containing solution on AH109A hepatoma-bearing rats. Biosci Biotechnol Biochem 62: 2418-2420, 1998.
59. Porter CW, Sufrin JR, Keith DD: Growth inhibition by methionine analog inhibitors of S-adenosylmethionine biosynthesis in the absence of polyamine depletion. Biochem Biophys Res Commun 122: 350-357, 1984.
60. Porter CW, Sufrin JR: Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Res 6: 525-542, 1986.
61. Breillout F, Poupon MF, Blanchard P, Lascaux V, Echinard-Garin P, Robert-Gero M: Association of SIBA treatment and a Metdepleted diet inhibits in vitro growth and in vivo metastatic spread of experimental tumor cell lines. Clin Exp Metastasis 6: 3-16, 1988.
62. Poirson-Bichat F, Lopez R, Bras GR, Miccoli L, Bourgeois Y, Demerseman P, Poisson M, Dutrillaux B, Poupon MF: Methionine deprivation and methionine analogs inhibit cell proliferation and growth of human xenografted gliomas. Life Sci 60: 919-931, 1997.
63. Rodriguez-Vicente J, Vicente-Ortega V, Canteras-Jordana M: The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines. Cancer 82: 495-502, 1998.
64. Yoshida S, Yamana H, Tanaka T, Ishibashi N, Toh U, Ishii H, Shirouzu Y, Shirouzu K: Effect of combination therapy with a methionine-mitomycin C conjugate and a methionine-deficient diet on tumor growth. In Vivo 12: 351-355, 1998.
65. Goseki N, Endo M, Onodera T, Kosaki G: Anti-tumor effect of L-methionine-deprived total parenteral nutrition with 5-fluorouracil administration on Yoshida sarcoma-bearing rats. Ann Surg 214: 83-88, 1991.
66. Hoshiya Y, Kubota T, Inada T, Kitajima M, Hoffman RM: Methionine-depletion modulates the efficacy of 5-fluorouracil in human gastric cancer in nude mice. Anticancer Res 17: 4371-4375, 1997.
67. Hoshiya Y, Kubota T, Matsuzaki SW, Kitajima M, Hoffman RM: Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice. Anticancer Res 16: 3515-3517, 1996.
68. Goseki N, Nagahama T, Maruyama M, Endo M: Enhanced anticancer effect of vincristine with methionine infusion after methionine-depleting total parenteral nutrition in tumor-bearing rats. Jpn J Cancer Res 87: 194-199, 1996.
69. Goseki N, Endo M: Thiol depletion and chemosensitization on nimustine hydrochloride by methionine-depleting total parenteral nutrition. Tohoku J Exp Med 161: 227-239, 1990.
70. Kokkinakis DM, Von WM, Vuong TH, Brent TP, Schold SCJ: Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br J Cancer 75: 779-788, 1997.
71. Goseki N, Yamazaki S, Endo M, Onodera T, Kosaki G, Hibino Y, Kuwahata T: Antitumor effect of methionine-depleting total parenteral nutrition with doxorubicin administration on Yoshida sarcoma-bearing rats. Cancer 69: 1865-1872, 1992.
72. Nagahama T, Goseki N, Endo M: Doxorubicin and vincristine with methionine depletion contributed to survival in the Yoshida sarcoma bearing rats. Anticancer Res 18: 25-31, 1998.
73. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
74. Suganuma M, Kawabe T, Hori H, Funabiki T, Okamoto T: Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res 59: 5887-5891, 1999.
75. Guo HY, Hoffman RM, Herrera H: Unchecked DNA synthesis and blocked cell division induced by methionine deprivation in a human prostate cancer cell line. In Vitro Cell Dev Biol Anim 29A: 359-361, 1993.
76. Lu S, Epner DE: Molecular mechanisms of cell cycle block by methionine restriction in human prostate cancer cells. Nutr Cancer, in press, 2001.
77. Meredith MJ, Cusick CL, Soltaninassab S, Sekhar KS, Lu S, Freeman ML: Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Biochem Biophys Res Commun 248: 458-463, 1998.
78. Wang ST, Chen HW, Sheen LY, Lii CK: Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr 127: 2135-2141, 1997.
79. Djurhuus R, Svardal AM, Mansoor MA, Ueland PM: Modulation of glutathione content and the effect on methionine auxotrophy and cellular distribution of homocysteine and cysteine in mouse cell lines. Carcinogenesis 12: 241-247, 1991.
80. Aw TY, Ookhtens M, Kaplowitz N: Mechanism of inhibition of glutathione efflux by methionine from isolated rat hepatocytes. Am J Physiol 251: G354-G361, 1986.
81. Story MD, Meyn RE: Modulation of apoptosis and enhancement of chemosensitivity by decreasing cellular thiols in a mouse B-cell lymphoma cell line that overexpresses bcl-2. Cancer Chemother Pharmacol 44: 362-366, 1999.
82. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP: S-Adenosylmethionine and methylation. FASEB J 10: 471-480, 1996.
83. Hoffman RM: Altered methionine metabolism and transmethylation in cancer. Anticancer Res 5: 1-30, 1985.
84. Hoffman RM: Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 738: 49-87, 1984.
85. Fiskerstrand T, Christensen B, Tysnes OB, Ueland PM, Refsum H: Development and reversion of methionine dependence in a human glioma cell line: relation to homocysteine remethylation and cobalamin status. Cancer Res 54: 4899-4906, 1994.
86. Tisdale MJ: Changes in tRNA methyltransferase activity and cellular S-adenosylmethionine content following methionine deprivation. Biochim Biophys Acta 609: 296-305, 1980.
87. Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, Endo M, Koike M, Takahashi H: Synergistic effect of methioninedepleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res 86: 484-489, 1995.
88. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang T, Waxman S, Wang ZY, Chen SJ: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324, 1999.